Innovation Pharmaceuticals (IPIX)

Executive Summary

Innovation Pharmaceuticals Inc. (IPIX) is a clinical-stage biopharmaceutical company developing Brilacidin, a first-in-class small molecule defensin mimetic with broad-spectrum antimicrobial and anti-inflammatory properties. The company also has an early-stage image-guided surgical laser platform, BEAMED, for oncology and neurology. As a Phase 1 company with no approved products, IPIX operates with a low market capitalization, reflecting high risk but significant upside potential if Brilacidin successfully progresses through clinical trials. The company’s near-term focus is on advancing Brilacidin into Phase 2 trials following completion of ongoing Phase 1 studies. Key risks include limited financial resources and the inherent uncertainty of early-stage drug development.

Upcoming Catalysts (preview)

• Q3 2026Brilacidin Phase 1 Data Readout70% success
• Q4 2026BEAMED Platform Preclinical Results40% success
• H2 2026Licensing or Partnership Deal for Brilacidin30% success